This site is intended for health professionals only
Monday 20 May 2019
Share |

Topic: plaque psoriasis

February 19, 2018
New data from VOYAGE 2 trial shows high efficacy response rates were achieved with continuous guselkumab treatment versus withdrawal

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving Tremfya® (guselkumab), who achieved at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1

 

November 25, 2016
Janssen has submitted an application to the EMA for the use of guselkumab for treatment of moderate to severe plaque psoriasis based on data from VOYAGE 1, VOYAGE 2, NAVIGATE and X-PLORE studies

 

Janssen-Cilag International announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis. Guselkumab is a human monoclonal antibody that targets the protein interleukin (IL)-23, which has been shown to play a key role in the development of immune-mediated inflammatory diseases.1

 

July 22, 2015
Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis

The National Institute for Health and Care Excellence (NICE) has issued technology appraisal guidance for Cosentyx™ (secukinumab). Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis who are candidates for systemic* therapy. (1)

 

May 27, 2015
Janssen-Cilag International NV (“Janssen”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for the use of STELARA® (ustekinumab), for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Janssen-Cilag International NV (“Janssen”) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for the use of STELARA® (ustekinumab), for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.
 

July 2, 2008
EMEA confirms positive benefit-risk balance for up to three years treatment with Raptiva

teaser

May 27, 2008
Data on psoriasis drug presented at EADV congress

teaser

January 18, 2008
Etanercept is highly effective in treating plaque psoriasis in children and adolescents, a trial reveals

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine